1
项与 161Tb-NYM032 相关的临床试验 / Not yet recruiting临床1/2期IIT Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.
100 项与 161Tb-NYM032 相关的临床结果
100 项与 161Tb-NYM032 相关的转化医学
100 项与 161Tb-NYM032 相关的专利(医药)
100 项与 161Tb-NYM032 相关的药物交易